Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$164.7
Market cap
$74.31B
P/E Ratio
30.9
Dividend/share
$1.73
EPS
$5.33
Enterprise value
$79.35B
Zoetis Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's
Highlights
The P/E is 23% lower than the 5-year quarterly average of 40.2 and 13% lower than the last 4 quarters average of 35.5
Zoetis's quick ratio has increased by 12% QoQ
Key stats
What are the main financial stats of ZTS
Market
Valuations
Earnings
Shares outstanding
451.17M
Market cap
$74.31B
Enterprise value
$79.35B
Price to book (P/B)
14.26
Price to sales (P/S)
8.15
EV/EBIT
24.22
EV/EBITDA
21.01
EV/Sales
8.67
Revenue
$9.15B
Gross profit
$6.41B
Net income
$2.43B
EBIT
$3.28B
EBITDA
$3.78B
Free cash flow
$2.31B
Per share
Balance sheet
Liquidity
EPS
$5.33
EPS diluted
$5.32
Free cash flow per share
$5.1
Book value per share
$11.55
Revenue per share
$20.21
TBVPS
$23.02
Total assets
$14.36B
Total liabilities
$9.12B
Debt
$6.76B
Equity
$5.23B
Working capital
$4.58B
Debt to equity
1.29
Current ratio
3.69
Quick ratio
1.84
Net debt/EBITDA
1.34
Margins
Efficiency
Dividend
EBITDA margin
41.3%
Gross margin
70.1%
Net margin
26.6%
Operating margin
35.9%
Return on assets
17%
Return on equity
48%
Return on invested capital
24.5%
Return on capital employed
25.9%
Return on sales
35.8%
Dividend yield
1.05%
DPS
$1.73
Payout ratio
32.4%
ZTS stock price
How has the Zoetis stock price performed over time
Intraday
0.26%
1 week
-3.57%
1 month
-6.93%
1 year
-15.53%
YTD
-16.55%
QTD
-15.7%
Financial performance
How have Zoetis's revenue and profit performed over time
Revenue
$9.15B
Gross profit
$6.41B
Operating income
$3.28B
Net income
$2.43B
Gross margin
70.1%
Net margin
26.6%
The gross profit has grown by 9% YoY and by 2.8% from the previous quarter
ZTS's revenue is up by 9% YoY and by 2.7% QoQ
The net income has grown by 7% YoY and by 3.7% from the previous quarter
Zoetis's operating income has increased by 5% YoY and by 5% QoQ
Growth
What is Zoetis's growth rate over time
Valuation
What is Zoetis stock price valuation
P/E
30.9
P/B
14.26
P/S
8.15
EV/EBIT
24.22
EV/EBITDA
21.01
EV/Sales
8.67
The P/E is 23% lower than the 5-year quarterly average of 40.2 and 13% lower than the last 4 quarters average of 35.5
Zoetis's EPS has increased by 8% YoY and by 4.3% QoQ
The stock's price to book (P/B) is 24% less than its 5-year quarterly average of 18.8 and 14% less than its last 4 quarters average of 16.6
ZTS's equity is up by 5% since the previous quarter and by 3.1% year-on-year
ZTS's price to sales (P/S) is 22% lower than its 5-year quarterly average of 10.4 and 14% lower than its last 4 quarters average of 9.5
ZTS's revenue is up by 9% YoY and by 2.7% QoQ
Efficiency
How efficient is Zoetis business performance
ZTS's return on assets is up by 6% year-on-year and by 3% since the previous quarter
ZTS's ROIC is up by 3.8% QoQ
Zoetis's return on sales has decreased by 4% YoY
The company's return on equity rose by 3% QoQ but it fell by 2% YoY
Dividends
What is ZTS's dividend history
DPS
$1.73
Dividend yield
1.05%
Payout ratio
32.4%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Zoetis financials performed over time
ZTS's total assets is 57% greater than its total liabilities
Zoetis's quick ratio has increased by 12% QoQ
The company's current ratio rose by 7% QoQ but it fell by 4.7% YoY
The debt is 29% higher than the equity
ZTS's equity is up by 5% since the previous quarter and by 3.1% year-on-year
Zoetis's debt to equity has decreased by 5% QoQ and by 3% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.